The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Syneron Medical missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP loss per share dropped.
Margins grew across the board.
Syneron Medical tallied revenue of $60.1 million. The five analysts polled by S&P Capital IQ looked for sales of $65.5 million on the same basis. GAAP reported sales were 5.5% higher than the prior-year quarter's $57.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.03. The five earnings estimates compiled by S&P Capital IQ predicted $0.04 per share. GAAP EPS were -$0.06 for Q3 against -$1.14 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 53.2%, 260 basis points better than the prior-year quarter. Operating margin was -3.6%, 6,130 basis points better than the prior-year quarter. Net margin was -3.8%, 6,660 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $72.7 million. On the bottom line, the average EPS estimate is $0.12.
Next year's average estimate for revenue is $268.8 million. The average EPS estimate is $0.24.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 719 members out of 753 rating the stock outperform, and 34 members rating it underperform. Among 199 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 191 give Syneron Medical a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Syneron Medical is buy, with an average price target of $17.38.
- Add Syneron Medical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Syneron Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Syneron Medical Ltd. Shares Are Looking Oh So Pretty
Syneron shares advance after reporting market-topping third-quarter results. Can shares head higher, or is the company now overvalued?
What Syneron Medical's Earnings Headlines Didn't Tell You
Don't just count the cash, time it.
Check This to Find Out Whether Syneron Medical Is Going to Bomb
Look here for a clue.